Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. (Q53147159)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 August 2012

Language	Label	Description	Also known as
English	Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.	scientific article published on 11 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. (English)

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Kazuaki Chayama

14

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

2

object named as

Hiroshi Aikata

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Tomokazu Kawaoka

1

object named as

Tomokazu Kawaoka

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Shoichi Takahashi

13

object named as

Shoichi Takahashi

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Akira Hiramatsu

11

object named as

Akira Hiramatsu

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Takashi Nakahara

4

object named as

Takashi Nakahara

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

9

object named as

Yuko Nagaoki

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

author name string

Eisuke Murakami

3

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Noriaki Naeshiro

5

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Mio Tanaka

6

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Yoji Honda

7

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Daisuke Miyaki

8

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Shintaro Takaki

10

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Koji Waki

12

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

publication date

11 August 2012

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

83

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

4

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

192-200

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Management of hepatocellular carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies?

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein1

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Identifiers

10.1159/000341347

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53147159&oldid=1891009537"